

Clinical Policy: Golimumab (Simponi, Simponi Aria)

Reference Number: CP.PHAR.253

Effective Date: 07.16

Last Review Date: 05.18

Line of Business: Medicaid, HIM*

[Coding Implications](#)

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Golimumab (Simponi[®], Simponi Aria[®]) is a tumor necrosis (TNF) blocker.

**For Health Insurance Marketplace (HIM), Simponi Aria is non-formulary and cannot be approved using these criteria; it is covered under the medical benefit only.*

FDA Approved Indication(s)

Simponi is indicated for the treatment of:

- Adult patients with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate (MTX)
- Adult patients with active psoriatic arthritis (PsA) alone, or in combination with methotrexate
- Adult patients with active ankylosing spondylitis (AS)
- Adult patients with moderately to severely active ulcerative colitis who have demonstrated corticosteroid dependence or who have had an inadequate response to or failed to tolerate oral aminosalicylates, oral corticosteroids, azathioprine, or 6-mercaptopurine (6-MP) for:
 - inducing and maintaining clinical response
 - improving endoscopic appearance of the mucosa during induction
 - inducing clinical remission
 - achieving and sustaining clinical remission in induction responders

Simponi Aria is indicated for the treatment of:

- Adult patients with moderately to severely active RA in combination with methotrexate
- Adult patients with active PsA
- Adult patients with active AS

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Simponi and Simponi Aria are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Rheumatoid Arthritis (must meet all):

1. Diagnosis of RA;
2. Prescribed by or in consultation with a rheumatologist;
3. Age \geq 18 years;

CLINICAL POLICY
Golimumab

4. Member meets one of the following (a or b):
 - a. Failure of a ≥ 3 consecutive month trial of MTX at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
 - b. If intolerance or contraindication to MTX (*see Appendix C*), failure of a ≥ 3 consecutive month trial of at least ONE conventional DMARD (e.g., sulfasalazine, leflunomide, hydroxychloroquine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of etanercept (*Enbrel[®] is preferred*) and adalimumab (*Humira[®] is preferred*), each used for ≥ 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization is required for etanercept and adalimumab*
6. Prescribed concomitantly with MTX, or another DMARD if intolerance or contraindication to MTX;
7. Dose does not exceed one of the following (a or b):
 - a. Simponi: 50 mg SC once monthly;
 - b. Simponi Aria: 2 mg/kg IV at weeks 0 and 4, followed by maintenance dose of 2 mg/kg every 8 weeks.

Approval duration:**Medicaid** - 6 months**HIM** - 6 months for Simponi (*medical benefit for Simponi Aria*)**B. Psoriatic Arthritis (must meet all):**

1. Diagnosis of PsA;
2. Prescribed in consultation with a dermatologist or rheumatologist;
3. Age ≥ 18 years;
4. Member meets one of the following (a or b):
 - a. Failure of a ≥ 3 consecutive month trial of MTX at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
 - b. If intolerance or contraindication to MTX (*see Appendix C*), failure of a ≥ 3 consecutive month trial of cyclosporine, sulfasalazine, or leflunomide at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of etanercept (*Enbrel is preferred*) AND adalimumab (*Humira is preferred*), each used for ≥ 3 consecutive months unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization is required for etanercept and adalimumab*
6. Dose does not exceed one of the following (a or b):
 - a. Simponi: 50 mg SC once monthly;
 - b. Simponi Aria: 2 mg/kg IV at weeks 0 and 4, followed by maintenance dose of 2 mg/kg every 8 weeks.

Approval duration:**Medicaid** - 6 months

HIM - 6 months for Simponi (*medical benefit for Simponi Aria*)

C. Ankylosing Spondylitis (must meet all):

1. Diagnosis of AS;
2. Prescribed by or in consultation with a rheumatologist;
3. Age \geq 18 years;
4. Failure of at least TWO non-steroidal anti-inflammatory drugs (NSAIDs) at up to maximally indicated doses, each used for \geq 4 weeks unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of etanercept (*Enbrel is preferred*) AND adalimumab (*Humira is preferred*), each used for \geq 3 consecutive months, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization is required for etanercept and adalimumab*
6. Dose does not exceed one of the following (a or b):
 - a. Simponi: 50 mg SC once monthly;
 - b. Simponi Aria: 2 mg/kg IV at weeks 0 and 4, followed by maintenance dose of 2 mg/kg every 8 weeks.

Approval duration:

Medicaid - 6 months

HIM - 6 months for Simponi (*medical benefit for Simponi Aria*)

D. Ulcerative Colitis (must meet all):

1. Diagnosis of UC;
2. Request is for Simponi (SC formulation);
3. Prescribed by or in consultation with a gastrointestinal (GI) specialist;
4. Age \geq 18 years;
5. Failure of a \geq 3 consecutive month trial of azathioprine, 6-MP, or an aminosalicylate (e.g., sulfasalazine) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
6. Failure of a \geq 3 consecutive month trial of adalimumab (*Humira is preferred*), unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization is required for adalimumab*
7. Dose does not exceed 200 mg at week 0, 100 mg at week 2, followed by maintenance dose of 100 mg every 4 weeks.

Approval duration: 6 months

E. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

CLINICAL POLICY
Golimumab

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed one of the following (a or b):
 - a. RA, PsA, AS (i or ii):
 - i. Simponi: 50 mg SC once monthly;
 - ii. Simponi Aria: 2 mg/kg IV every 8 weeks;
 - b. UC (Simponi): 100 mg SC every 4 weeks.

Approval duration:

Medicaid - 12 months

HIM – 12 months for Simponi (*medical benefit for Simponi Aria*)

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

1. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – HIM.PHAR.21 for health insurance marketplace and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

6MP: 6-mercaptopurine

AS: ankylosing spondylitis

DMARD: disease-modifying
antirheumatic drug

FDA: Food and Drug Administration

GI: gastrointestinal

MTX: methotrexate

NSAID: non-steroidal anti-inflammatory
drug

PsA: psoriatic arthritis

RA: rheumatoid arthritis

TNF: tumor necrosis factor

UC: ulcerative colitis

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent and may require prior authorization.

CLINICAL POLICY
Golimumab

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
azathioprine (Azasan [®] , Imuran [®])	RA 1 mg/kg/day PO QD or divided BID UC* 1.5 – 2 mg/kg/day PO	2.5 mg/kg/day
Cuprimine [®] (d-penicillamine)	RA* <u>Initial dose:</u> 125 or 250 mg PO QD <u>Maintenance dose:</u> 500 – 750 mg/day PO QD	1,500 mg/day
cyclosporine (Sandimmune [®] , Neoral [®])	PsA* 2.5 – 3 mg/kg/day PO QD RA 2.5 – 4 mg/kg/day PO divided BID	PsA: 3 mg/kg/day RA: 4 mg/kg/day
hydroxychloroquine (Plaquenil [®])	RA* <u>Initial dose:</u> 400 – 600 mg PO QD <u>Maintenance dose:</u> 200 – 400 mg PO QD	600 mg/day
leflunomide (Arava [®])	PsA* 100 mg/day PO loading dose for 3 days followed by 20 mg/day PO RA 100 mg PO QD for 3 days, then 20 mg PO QD	20 mg/day
6-mercaptopurine (Purixan [®])	UC* 50 mg PO QD or 1 – 2 mg/kg/day PO	2 mg/kg/day
methotrexate (Rheumatrex [®])	PsA* 7.5 – 15 mg/week PO RA 7.5 mg/week PO, SC, or IM or 2.5 mg PO Q12 hr for 3 doses/week UC* 15 – 25 mg/week IM or SC	30 mg/week
NSAIDs (e.g., indomethacin, ibuprofen,	AS Varies	Varies

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
naproxen, celecoxib)		
Pentasa® (mesalamine)	UC 1,000 mg PO QID	4 g/day
sulfasalazine (Azulfidine®)	PsA* 2,000 mg/day PO RA 2 gm/day PO in divided doses UC <u>Initial dose:</u> 3 – 4 g/day PO in divided doses (not to exceed Q8 hrs) <u>Maintenance dose:</u> 2 g/day PO QD	PsA: 5 g/day RA: 3 g/day UC: 4 g/day
Enbrel® (etanercept)	AS 50 mg SC once weekly PsA, RA 25 mg SC twice weekly or 50 mg SC once weekly	50 mg/week
Humira® (adalimumab)	AS, PsA 40 mg SC every other week RA 40 mg SC every other week (may increase to once weekly) UC <u>Initial dose:</u> 160 mg SC on Day 1, then 80 mg SC on Day 15 <u>Maintenance dose:</u> 40 mg SC every other week starting on Day 29	AS, PsA, UC: 40 mg every other week RA: 40 mg/week

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

*Off-label

Appendix C: General Information

- Ankylosing Spondylitis:

CLINICAL POLICY
Golimumab

- Several AS treatment guidelines call for a trial of 2 or 3 NSAIDs prior to use of an anti-TNF agent. A two year trial showed that continuous NSAID use reduced radiographic progression of AS versus on demand use of NSAID.
- Definition of failure of MTX or DMARDs
 - Child-bearing age is not considered a contraindication for use of MTX. Each drug has risks in pregnancy. An educated patient and family planning would allow use of MTX in patients who have no intention of immediate pregnancy.
 - Social use of alcohol is not considered a contraindication for use of MTX. MTX may only be contraindicated if patients choose to drink over 14 units of alcohol per week. However, excessive alcohol drinking can lead to worsening of the condition, so patients who are serious about clinical response to therapy should refrain from excessive alcohol consumption.
- Examples of positive response to therapy may include, but are not limited to:
 - Reduction in joint pain/swelling/tenderness
 - Improvement in ESR/CRP levels
 - Improvements in activities of daily living

V. Dosage and Administration

Drug Name	Indication	Dosing Regimen	Maximum Dose
Golimumab (Simponi)	AS	50 mg SC once monthly	50 mg/month
	PsA		
	RA		
	UC	<u>Initial dose:</u> 200 mg SC at week 0, then 100 mg SC at week 2 <u>Maintenance dose:</u> 100 mg SC every 4 weeks	100 mg every 4 weeks
Golimumab (Simponi Aria)	AS	<u>Initial dose:</u>	2 mg/kg every 8 weeks
	PsA	2 mg/kg IV at weeks 0 and 4	
	RA	<u>Maintenance dose:</u> 2 mg/kg IV every 8 weeks	

VI. Product Availability

Drug Name	Availability
Golimumab (Simponi)	Single-dose prefilled SmartJect [®] autoinjector: 50 mg/0.5 mL, 100 mg/1 mL Single-dose prefilled syringe: 50 mg/0.5 mL, 100 mg/1 mL
Golimumab (Simponi Aria)	Single-use vial: 50 mg/4 mL

VII. References

1. Simponi Prescribing Information. Horsham, PA; Janssen Biotech; February 2018. Available at <http://www.simponi.com/shared/product/simponi/prescribing-information.pdf>. Accessed February 27, 2018.

CLINICAL POLICY

Golimumab

2. Simponi Aria Prescribing Information. Horsham, PA; Janssen Biotech; February 2018. Available at <http://simponiaria.com/sites/default/files/prescribing-information.pdf>. Accessed February 27, 2018.
3. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis*. 2017; 0: 1-18.
4. Singh JA, Saag KG, Bridges SL, et al. 2015 American College of Rheumatology Guidelines for the Treatment of Rheumatoid Arthritis. *Arthritis Care & Research* 2015; 68(1):1-26.
5. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. *J Am Acad Dermatol*. 2011;65(1):137-174.
6. Menter A, Gottlieb A, Feldman SR, et al. Guidelines for the management of psoriasis and psoriatic arthritis. Section 1: Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *J Am Acad Dermatol*. 2008;58(5):826-850.
7. Ward MM, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis & Rheumatology*, 2015. DOI 10.1002/ART.39298.
8. Braun J, van den berg R, et al. 2010 Update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Am Rheu Dis*. 2011: 70; 896-904.
9. Kornbluth A, Sachar DB. Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee. *Am J Gastroenterol*. 2010;105:501-523.
10. Dassopoulos T, Cohen R, Scherl E, et al. Ulcerative Colitis Clinical Care Pathway. American Gastroenterological Association. 2015. Available at <http://campaigns.gastro.org/algorithms/UlcerativeColitis/>. Accessed June 23, 2017.

Coding Implications –

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1602	Injection, golimumab, 1 mg, for intravenous use

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy split from CP.PHAR.86.ArthritisTreatments, CP.PHAR.85 Psoriasis Treatments, CP.PHAR.87.IBD Treatment_4. RA, PsA, AS, UC: Removed criteria related to HBV, malignant disease, concomitant use with other biologics, and concurrent administration of live vaccines; added dosing limits/details; added	06.16	07.16

CLINICAL POLICY
Golimumab

Reviews, Revisions, and Approvals	Date	P&T Approval Date
<p>requirement for trial and failure of PDL Enbrel and Humira, unless contraindicated (just Humira for UC); RA: changed age requirement to 18; modified criteria to require trial of MTX unless contraindicated; added sulfasalazine and hydroxychloroquine as alternatives to MTX if contraindicated; Simponi Aria indication RA only per PI. Re-auth: combined into All Indications; added criteria related to dosing and reasons to discontinue. Modified approval duration to 6 months for initial and 12 months for renewal. Shortened background section.</p>		
<p>PsA: Preferred trial of MTX above other DMARDs per CPC feedback. UC: removed option of trial of aminosaliclates per 2015 AGA Clinical Care Pathway.</p>	11.16	
<p>Converted to new template. RA: modified the RA diagnostic criteria from requiring one or more of the following: ≥ 5 inflamed joints, elevation in the ESR and/or CRP concentration; positive rheumatoid factor and/or anticyclic citrullinated peptide) antibodies (present in most patients), evidence of inflammation on plain radiography of the hands, wrists, or feet, such as osteopenia and/or periarticular swelling, to the ACR diagnostic criteria. Removed requirement for use in combination with MTX. PsA, AS, UC: clarified request must be for Simponi. For UC, limited accepted first line trials to thiopurine.</p>	07.17	07.17
<p>Added additionally FDA-approved indications of PsA and AS for Simponi Aria. For PsA, removed hydroxycloquine as an accepted trial and replaced it with cyclosporine to align with similar policies for PsA. This was a typo.</p>	01.11.18	
<p>2Q 2018 annual review: policies combined for HIM and Medicaid lines of business; HIM: removed specific diagnosis requirements for RA, modified trial and failure for RA, AS, PsA to require both Humira and Enbrel, removed trial and failure of Enbrel from UC as Enbrel is not indicated; Medicaid: added requirement for concomitant use of MTX or another DMARD for RA; Medicaid and HIM: modified trial and failure for RA to at least one conventional DMARD, removed TB testing for all indications, added aminosaliclylate as an option for trial and failure for UC, modified gastroenterologist specialty requirement to gastrointestinal specialist for UC; references reviewed and updated.</p>	02.27.18	05.18

Important Reminder

CLINICAL POLICY

Golimumab

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

CLINICAL POLICY
Golimumab

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.